Ownership history in XTX Topco Ltd Β· 11 quarters on record
This page tracks every 13F SEC filing in which XTX Topco Ltd reported a position in ATOSSA THERAPEUTICS INC (ATOS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π XTX Topco Ltd underperformed the S&P 500 by β58.9% annually on this ATOS position. Timing score: 20% (2/10 decisions correct). Average cost basis: $12.86. Maximum drawdown during holding period: β72.0%.
β Significantly underperformed the S&P 500 by 58.9% ann.
10 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
2 of 10 add/trim decisions correct
Best entry: $8.85 (2025 Q4) Β· Worst: $31.65 (2021 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
7 adds Β· 4 trims. Bought during 4 of 6 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size